Growth in the Wound Care segment
At EUR 565.2 million, sales in the Wound Care segment were EUR 72.8 million over the previous year. Organic sales growth stood at 12.1%. This growth is the result of an active pricing strategy, successful development in advanced wound care and the recovery of traditional wound care, following the coronavirus pandemic among other things.
The number of surgeries and visits to doctors and pharmacies continued to grow in the course of the year, in Europe above all, which had a positive impact on the demand for wound care products. Growth was driven, in particular, by the new ranges of silicone-covered and post-operative wound dressings, non-adhesive fixation products and Vivano® products for vacuum-assisted wound therapy.
Alongside the clear growth in sales, organizational measures to improve efficiency have helped further increase profitability in the Wound Care segment. Adjusted EBITDA rose in the reporting year by EUR 14.1 million to EUR 100.9 million.
Increase in sales in the Incontinence Management segment
Sales revenues in the Incontinence Management segment stood at EUR 720.8 million in the reporting year. The organic sales growth of 4.5% is in particular attributable to the necessary price adjustments resulting from increased costs. In addition, the volume attributable to care homes grew due to the higher bed occupancy rate. This ensures increased demand for incontinence products.
The ranges with particularly strong sales during the reporting year included both the unisex, at 8.6%, and the gender-specific disposable pants first introduced a few years ago, which were up 17.7% compared to the previous year, with incontinence pads up 5.8% and the Vala® disposable care range up 9.6%.
The reporting year was affected by considerable increases in raw material and transport costs. Cost-cutting measures and price adjustments were only able to partially compensate for these developments. Adjusted EBITDA in the Incontinence Management segment in 2022 was EUR 68.6 million, and hence EUR 19.3 million below that of the previous year.
Infection Management sales decline
The Infection Management segment reported sales revenues of EUR 557.7 million in 2022. This represents a serious decline in sales, of -18.8%, the main drivers being in the examination gloves and sanitizer ranges.
The examination gloves range suffered a fall in demand in light of the coronavirus pandemic's transition to an endemic phase. Sales in examination gloves were down due to the price drop. In surgery-related areas, kits and coverings performed positively thanks to imposed price rises and volume gains.
The clear decline in sales in the area of Disinfection Management was due to the shift away from the special pandemic-related circumstances of the preceding years. Due to customers holding high levels of stock, demand dropped for hand sanitizer in particular. In terms of income, price increases could not compensate for this development or the increased raw materials prices.
In this context, adjusted EBITDA in the Infection Management segment fell by EUR 19.6 million to EUR 17.8 million.
Diminishing results in Complementary Group Divisions
Sales revenues in the Complementary Group Divisions segment stood at EUR 467.9 million in 2022. This equates to an organic increase in sales of 4.4%. In all areas the significant cost increases led to declining business performance. At EUR 3.6 million, adjusted EBITDA for the reporting year in the Complementary Group Divisions segment was significantly below the EUR 28.7 million of the previous year.
Like the KOB Group, the CMC Group achieved organic sales growth. For CMC, this was largely as a result of an increase in the sales prices of cotton wool products, whereas for the KOB Group it was thanks to positive performance in relation to compression bandages. In 2022, the KNEIPP Group was confronted with shrinking markets in Europe and strong price pressure in the bath product categories. Here, consumers increasingly opted for cheaper products.